Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. | After a ...

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive, mature data from its ...

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...

Merck's bumpy six-year relationship with Eisai's anti-cancer medication Lenvima landed on somewhat better footing in Spain ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

The study found that lenvatinib continued to demonstrate improved efficacy in patients with radioiodine-refractory ...

Median PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...

Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...